OXIS International, Inc. engaged in the research, development and sale of products that counteract the harmful effects of oxidative stress. Oxidative stress refers to the situations in which the body’s antioxidant and other defensive abilities to combat free radicals (a.k.a highly reactive species of oxygen and nitrogen) are overwhelmed and one’s normal healthy balance is either lost or severely compromised.

Oxis' primary goal is developing and marketing the highest quality products available to combat and counter-act effects of oxidative stress. In Oxis' product development which includes products targeted at heart health, brain health, and resistance against diseases, anti aging, skin care, inflammation (arthritis, joint pain), liver detoxification and blood sugar regulation.

The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.

Extensive data has been obtained by researchers worldwide on the presence of l-ergothioneine in human tissues. In addition to this potent antioxidant, Oxis also has an extensive patent portfolio and a portfolio of therapeutic compounds. The company has conducted early stage development of molecules that target different disease indications, including BXT 51072 and Glutathione Mimics, Lipid Soluble Antioxidants, and Superoxide Dismutase (SOD). Further information on each compound (s) is available on their website at http://www.oxis.com.

Another source for information update can follow at Oxis on Twitter. You can also find Oxis on facebook to share about their lovely products.